CIPROFLOXACIN TABLETS
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
16-09-2019
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)
Available from:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC code:
J01MA02
INN (International Name):
CIPROFLOXACIN
Dosage:
250MG
Pharmaceutical form:
TABLET
Composition:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250MG
Administration route:
ORAL
Units in package:
100
Prescription type:
Prescription
Therapeutic area:
QUINOLONES
Product summary:
Active ingredient group (AIG) number: 0123207006; AHFS:
Authorization status:
APPROVED
Authorization date:
2009-08-20
Summary of Product characteristics
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPROFLOXACIN TABLETS
Ciprofloxacin Tablets USP
250 MG, 500 MG, 750 MG CIPROFLOXACIN AS CIPROFLOXACIN HYDROCHLORIDE
ANTIBACTERIAL AGENT
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision:
September 16, 2019
Submission Control No: 229183
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................3
SUMMARY PRODUCT INFORMATION
...................................................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................................................3
CONTRAINDICATIONS
..............................................................................................................................7
WARNINGS AND PRECAUTIONS
............................................................................................................7
ADVERSE REACTIONS
............................................................................................................................
13
DRUG INTERACTIONS
.............................................................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................................................
24
OVERDOSAGE
...........................................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
27
STORAGE AND STABILITY
....................................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................................
29
PART II: SCIENTIFIC INFORMATION
...........
Read the complete document
